

Eosinophilic Granulomatosis Treatment Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/E2E3E1CE0C7BEN.html>

Date: February 2022

Pages: 68

Price: US\$ 3,250.00 (Single User License)

ID: E2E3E1CE0C7BEN

Abstracts

Eosinophilic Granulomatosis is a rare autoimmune disease usually characterized by acute asthma, vascular inflammation, and high levels of eosinophilic granulosis. Eosinophilic granulomatosis affects various organs such as the lungs, skin, gastrointestinal tract, heart, and nervous system. Eosinophilic granuloma is divided into three stages, namely, allergic, eosinophilic, and vascular. Eosinophilic granulomatosis begins with the development of allergies and asthma

This report contains market size and forecasts of Eosinophilic Granulomatosis Treatment in Global, including the following market information:

Global Eosinophilic Granulomatosis Treatment Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Eosinophilic Granulomatosis Treatment market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

By Drug Type Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Eosinophilic Granulomatosis Treatment include AstraZeneca plc, GlaxoSmithKline LLC, Baxter Healthcare Corporation, Genentech Inc,

Teva Pharmaceutical Industries Ltd, Koninklijke DSM NV, Novartis International AG and Pharma Holdings, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Eosinophilic Granulomatosis Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Eosinophilic Granulomatosis Treatment Market, by Type, 2017-2022, 2023-2028
(\$ millions)

Global Eosinophilic Granulomatosis Treatment Market Segment Percentages, by Type, 2021 (%)

By Drug Type

Mepolizumab

Rituximab

Benralizumab

Omalizumab

Methotrexate Sodium

Others

By Route of Administration

Oral

Intravenous

Intramuscular

Global Eosinophilic Granulomatosis Treatment Market, by Application, 2017-2022,
2023-2028 (\$ millions)

Global Eosinophilic Granulomatosis Treatment Market Segment Percentages, by
Application, 2021 (%)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Global Eosinophilic Granulomatosis Treatment Market, By Region and Country,
2017-2022, 2023-2028 (\$ Millions)

Global Eosinophilic Granulomatosis Treatment Market Segment Percentages, By
Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Eosinophilic Granulomatosis Treatment revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Eosinophilic Granulomatosis Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

AstraZeneca plc

GlaxoSmithKline LLC

Baxter Healthcare Corporation

Genentech Inc

Teva Pharmaceutical Industries Ltd

Koninklijke DSM NV

Novartis International AG

Pharma Holdings

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Eosinophilic Granulomatosis Treatment Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Eosinophilic Granulomatosis Treatment Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL EOSINOPHILIC GRANULOMATOSIS TREATMENT OVERALL MARKET SIZE

- 2.1 Global Eosinophilic Granulomatosis Treatment Market Size: 2021 VS 2028
- 2.2 Global Eosinophilic Granulomatosis Treatment Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Eosinophilic Granulomatosis Treatment Players in Global Market
- 3.2 Top Global Eosinophilic Granulomatosis Treatment Companies Ranked by Revenue
- 3.3 Global Eosinophilic Granulomatosis Treatment Revenue by Companies
- 3.4 Top 3 and Top 5 Eosinophilic Granulomatosis Treatment Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Eosinophilic Granulomatosis Treatment Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Eosinophilic Granulomatosis Treatment Players in Global Market
 - 3.6.1 List of Global Tier 1 Eosinophilic Granulomatosis Treatment Companies
 - 3.6.2 List of Global Tier 2 and Tier 3 Eosinophilic Granulomatosis Treatment

Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Eosinophilic Granulomatosis Treatment Market Size Markets, 2021 & 2028

4.1.2 Mepolizumab

4.1.3 Rituximab

4.1.4 Benralizumab

4.1.5 Omalizumab

4.1.6 Methotrexate Sodium

4.1.7 Others

4.2 By Type - Global Eosinophilic Granulomatosis Treatment Revenue & Forecasts

4.2.1 By Type - Global Eosinophilic Granulomatosis Treatment Revenue, 2017-2022

4.2.2 By Type - Global Eosinophilic Granulomatosis Treatment Revenue, 2023-2028

4.2.3 By Type - Global Eosinophilic Granulomatosis Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Eosinophilic Granulomatosis Treatment Market Size, 2021 & 2028

5.1.2 Hospital Pharmacies

5.1.3 Retail Pharmacies

5.1.4 Online Pharmacies

5.2 By Application - Global Eosinophilic Granulomatosis Treatment Revenue & Forecasts

5.2.1 By Application - Global Eosinophilic Granulomatosis Treatment Revenue, 2017-2022

5.2.2 By Application - Global Eosinophilic Granulomatosis Treatment Revenue, 2023-2028

5.2.3 By Application - Global Eosinophilic Granulomatosis Treatment Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Eosinophilic Granulomatosis Treatment Market Size, 2021 &

2028

6.2 By Region - Global Eosinophilic Granulomatosis Treatment Revenue & Forecasts

6.2.1 By Region - Global Eosinophilic Granulomatosis Treatment Revenue, 2017-2022

6.2.2 By Region - Global Eosinophilic Granulomatosis Treatment Revenue, 2023-2028

6.2.3 By Region - Global Eosinophilic Granulomatosis Treatment Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Eosinophilic Granulomatosis Treatment Revenue, 2017-2028

6.3.2 US Eosinophilic Granulomatosis Treatment Market Size, 2017-2028

6.3.3 Canada Eosinophilic Granulomatosis Treatment Market Size, 2017-2028

6.3.4 Mexico Eosinophilic Granulomatosis Treatment Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Eosinophilic Granulomatosis Treatment Revenue, 2017-2028

6.4.2 Germany Eosinophilic Granulomatosis Treatment Market Size, 2017-2028

6.4.3 France Eosinophilic Granulomatosis Treatment Market Size, 2017-2028

6.4.4 U.K. Eosinophilic Granulomatosis Treatment Market Size, 2017-2028

6.4.5 Italy Eosinophilic Granulomatosis Treatment Market Size, 2017-2028

6.4.6 Russia Eosinophilic Granulomatosis Treatment Market Size, 2017-2028

6.4.7 Nordic Countries Eosinophilic Granulomatosis Treatment Market Size, 2017-2028

6.4.8 Benelux Eosinophilic Granulomatosis Treatment Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Eosinophilic Granulomatosis Treatment Revenue, 2017-2028

6.5.2 China Eosinophilic Granulomatosis Treatment Market Size, 2017-2028

6.5.3 Japan Eosinophilic Granulomatosis Treatment Market Size, 2017-2028

6.5.4 South Korea Eosinophilic Granulomatosis Treatment Market Size, 2017-2028

6.5.5 Southeast Asia Eosinophilic Granulomatosis Treatment Market Size, 2017-2028

6.5.6 India Eosinophilic Granulomatosis Treatment Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Eosinophilic Granulomatosis Treatment Revenue, 2017-2028

6.6.2 Brazil Eosinophilic Granulomatosis Treatment Market Size, 2017-2028

6.6.3 Argentina Eosinophilic Granulomatosis Treatment Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Eosinophilic Granulomatosis Treatment Revenue, 2017-2028

6.7.2 Turkey Eosinophilic Granulomatosis Treatment Market Size, 2017-2028

- 6.7.3 Israel Eosinophilic Granulomatosis Treatment Market Size, 2017-2028
- 6.7.4 Saudi Arabia Eosinophilic Granulomatosis Treatment Market Size, 2017-2028
- 6.7.5 UAE Eosinophilic Granulomatosis Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 AstraZeneca plc

- 7.1.1 AstraZeneca plc Corporate Summary
- 7.1.2 AstraZeneca plc Business Overview
- 7.1.3 AstraZeneca plc Eosinophilic Granulomatosis Treatment Major Product Offerings
- 7.1.4 AstraZeneca plc Eosinophilic Granulomatosis Treatment Revenue in Global Market (2017-2022)
- 7.1.5 AstraZeneca plc Key News

7.2 GlaxoSmithKline LLC

- 7.2.1 GlaxoSmithKline LLC Corporate Summary
- 7.2.2 GlaxoSmithKline LLC Business Overview
- 7.2.3 GlaxoSmithKline LLC Eosinophilic Granulomatosis Treatment Major Product Offerings
- 7.2.4 GlaxoSmithKline LLC Eosinophilic Granulomatosis Treatment Revenue in Global Market (2017-2022)
- 7.2.5 GlaxoSmithKline LLC Key News

7.3 Baxter Healthcare Corporation

- 7.3.1 Baxter Healthcare Corporation Corporate Summary
- 7.3.2 Baxter Healthcare Corporation Business Overview
- 7.3.3 Baxter Healthcare Corporation Eosinophilic Granulomatosis Treatment Major Product Offerings
- 7.3.4 Baxter Healthcare Corporation Eosinophilic Granulomatosis Treatment Revenue in Global Market (2017-2022)
- 7.3.5 Baxter Healthcare Corporation Key News

7.4 Genentech Inc

- 7.4.1 Genentech Inc Corporate Summary
- 7.4.2 Genentech Inc Business Overview
- 7.4.3 Genentech Inc Eosinophilic Granulomatosis Treatment Major Product Offerings
- 7.4.4 Genentech Inc Eosinophilic Granulomatosis Treatment Revenue in Global Market (2017-2022)
- 7.4.5 Genentech Inc Key News

7.5 Teva Pharmaceutical Industries Ltd

- 7.5.1 Teva Pharmaceutical Industries Ltd Corporate Summary
- 7.5.2 Teva Pharmaceutical Industries Ltd Business Overview

7.5.3 Teva Pharmaceutical Industries Ltd Eosinophilic Granulomatosis Treatment Major Product Offerings

7.5.4 Teva Pharmaceutical Industries Ltd Eosinophilic Granulomatosis Treatment Revenue in Global Market (2017-2022)

7.5.5 Teva Pharmaceutical Industries Ltd Key News

7.6 Koninklijke DSM NV

7.6.1 Koninklijke DSM NV Corporate Summary

7.6.2 Koninklijke DSM NV Business Overview

7.6.3 Koninklijke DSM NV Eosinophilic Granulomatosis Treatment Major Product Offerings

7.6.4 Koninklijke DSM NV Eosinophilic Granulomatosis Treatment Revenue in Global Market (2017-2022)

7.6.5 Koninklijke DSM NV Key News

7.7 Novartis International AG

7.7.1 Novartis International AG Corporate Summary

7.7.2 Novartis International AG Business Overview

7.7.3 Novartis International AG Eosinophilic Granulomatosis Treatment Major Product Offerings

7.7.4 Novartis International AG Eosinophilic Granulomatosis Treatment Revenue in Global Market (2017-2022)

7.7.5 Novartis International AG Key News

7.8 Pharma Holdings

7.8.1 Pharma Holdings Corporate Summary

7.8.2 Pharma Holdings Business Overview

7.8.3 Pharma Holdings Eosinophilic Granulomatosis Treatment Major Product Offerings

7.8.4 Pharma Holdings Eosinophilic Granulomatosis Treatment Revenue in Global Market (2017-2022)

7.8.5 Pharma Holdings Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Eosinophilic Granulomatosis Treatment Market Opportunities & Trends in Global Market

Table 2. Eosinophilic Granulomatosis Treatment Market Drivers in Global Market

Table 3. Eosinophilic Granulomatosis Treatment Market Restraints in Global Market

Table 4. Key Players of Eosinophilic Granulomatosis Treatment in Global Market

Table 5. Top Eosinophilic Granulomatosis Treatment Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Eosinophilic Granulomatosis Treatment Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Eosinophilic Granulomatosis Treatment Revenue Share by Companies, 2017-2022

Table 8. Global Companies Eosinophilic Granulomatosis Treatment Product Type

Table 9. List of Global Tier 1 Eosinophilic Granulomatosis Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Eosinophilic Granulomatosis Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Eosinophilic Granulomatosis Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Eosinophilic Granulomatosis Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Eosinophilic Granulomatosis Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Eosinophilic Granulomatosis Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Eosinophilic Granulomatosis Treatment Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Eosinophilic Granulomatosis Treatment Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Eosinophilic Granulomatosis Treatment Revenue,

(US\$, Mn), 2017-2022

Table 21. By Country - North America Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2023-2028

Table 30. AstraZeneca plc Corporate Summary

Table 31. AstraZeneca plc Eosinophilic Granulomatosis Treatment Product Offerings

Table 32. AstraZeneca plc Eosinophilic Granulomatosis Treatment Revenue (US\$, Mn), (2017-2022)

Table 33. GlaxoSmithKline LLC Corporate Summary

Table 34. GlaxoSmithKline LLC Eosinophilic Granulomatosis Treatment Product Offerings

Table 35. GlaxoSmithKline LLC Eosinophilic Granulomatosis Treatment Revenue (US\$, Mn), (2017-2022)

Table 36. Baxter Healthcare Corporation Corporate Summary

Table 37. Baxter Healthcare Corporation Eosinophilic Granulomatosis Treatment Product Offerings

Table 38. Baxter Healthcare Corporation Eosinophilic Granulomatosis Treatment Revenue (US\$, Mn), (2017-2022)

Table 39. Genentech Inc Corporate Summary

Table 40. Genentech Inc Eosinophilic Granulomatosis Treatment Product Offerings

Table 41. Genentech Inc Eosinophilic Granulomatosis Treatment Revenue (US\$, Mn), (2017-2022)

Table 42. Teva Pharmaceutical Industries Ltd Corporate Summary

Table 43. Teva Pharmaceutical Industries Ltd Eosinophilic Granulomatosis Treatment

Product Offerings

Table 44. Teva Pharmaceutical Industries Ltd Eosinophilic Granulomatosis Treatment Revenue (US\$, Mn), (2017-2022)

Table 45. Koninklijke DSM NV Corporate Summary

Table 46. Koninklijke DSM NV Eosinophilic Granulomatosis Treatment Product Offerings

Table 47. Koninklijke DSM NV Eosinophilic Granulomatosis Treatment Revenue (US\$, Mn), (2017-2022)

Table 48. Novartis International AG Corporate Summary

Table 49. Novartis International AG Eosinophilic Granulomatosis Treatment Product Offerings

Table 50. Novartis International AG Eosinophilic Granulomatosis Treatment Revenue (US\$, Mn), (2017-2022)

Table 51. Pharma Holdings Corporate Summary

Table 52. Pharma Holdings Eosinophilic Granulomatosis Treatment Product Offerings

Table 53. Pharma Holdings Eosinophilic Granulomatosis Treatment Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

- Figure 1. Eosinophilic Granulomatosis Treatment Segment by Type in 2021
- Figure 2. Eosinophilic Granulomatosis Treatment Segment by Application in 2021
- Figure 3. Global Eosinophilic Granulomatosis Treatment Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Eosinophilic Granulomatosis Treatment Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Eosinophilic Granulomatosis Treatment Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Eosinophilic Granulomatosis Treatment Revenue in 2021
- Figure 8. By Type - Global Eosinophilic Granulomatosis Treatment Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Eosinophilic Granulomatosis Treatment Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Eosinophilic Granulomatosis Treatment Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Eosinophilic Granulomatosis Treatment Revenue Market Share, 2017-2028
- Figure 12. US Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Eosinophilic Granulomatosis Treatment Revenue Market Share, 2017-2028
- Figure 16. Germany Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 21. Nordic Countries Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Eosinophilic Granulomatosis Treatment Revenue Market Share, 2017-2028

Figure 24. China Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 28. India Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Eosinophilic Granulomatosis Treatment Revenue Market Share, 2017-2028

Figure 30. Brazil Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Eosinophilic Granulomatosis Treatment Revenue Market Share, 2017-2028

Figure 33. Turkey Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Eosinophilic Granulomatosis Treatment Revenue, (US\$, Mn), 2017-2028

Figure 37. AstraZeneca plc Eosinophilic Granulomatosis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. GlaxoSmithKline LLC Eosinophilic Granulomatosis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Baxter Healthcare Corporation Eosinophilic Granulomatosis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Genentech Inc Eosinophilic Granulomatosis Treatment Revenue Year Over

Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Teva Pharmaceutical Industries Ltd Eosinophilic Granulomatosis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Koninklijke DSM NV Eosinophilic Granulomatosis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Novartis International AG Eosinophilic Granulomatosis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Pharma Holdings Eosinophilic Granulomatosis Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Eosinophilic Granulomatosis Treatment Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/E2E3E1CE0C7BEN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E2E3E1CE0C7BEN.html>